10.92 USD
-0.39 (-3.45%)
10.92 USD
0 (0%)
Taking everything into account, FULC scores 4 out of 10 in our fundamental rating. FULC was compared to 191 industry peers in the Pharmaceuticals industry. FULC has a great financial health rating, but its profitability evaluates not so good. FULC has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
FULC had negative earnings in the past year.
FULC had a negative operating cash flow in the past year.
In the past 5 years FULC always reported negative net income.
In the past 5 years FULC always reported negative operating cash flow.
1.2 Ratios
FULC's Return On Assets of -4.53% is fine compared to the rest of the industry. FULC outperforms 72.25% of its industry peers.
FULC has a Return On Equity of -4.90%. This is in the better half of the industry: FULC outperforms 76.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.53% | ||
| ROE | -4.9% | ||
| ROIC | N/A |
ROA(3y)-29.99%
ROA(5y)-35.8%
ROE(3y)-33.54%
ROE(5y)-42.65%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
FULC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
FULC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for FULC has been reduced compared to 1 year ago.
The number of shares outstanding for FULC has been increased compared to 5 years ago.
There is no outstanding debt for FULC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
FULC has an Altman-Z score of 19.68. This indicates that FULC is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 19.68, FULC belongs to the best of the industry, outperforming 87.96% of the companies in the same industry.
There is no outstanding debt for FULC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 19.68 |
ROIC/WACCN/A
WACC9.36%
2.3 Liquidity
FULC has a Current Ratio of 17.70. This indicates that FULC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 17.70, FULC belongs to the top of the industry, outperforming 87.96% of the companies in the same industry.
FULC has a Quick Ratio of 17.70. This indicates that FULC is financially healthy and has no problem in meeting its short term obligations.
FULC has a Quick ratio of 17.70. This is amongst the best in the industry. FULC outperforms 87.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 17.7 | ||
| Quick Ratio | 17.7 |
3. Growth
3.1 Past
FULC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -280.65%.
The Revenue has grown by 2752.05% in the past year. This is a very strong growth!
Measured over the past years, FULC shows a very strong growth in Revenue. The Revenue has been growing by 61.03% on average per year.
EPS 1Y (TTM)-280.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.43%
Revenue 1Y (TTM)2752.05%
Revenue growth 3Y61.03%
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to decrease by -27.38% on average over the next years. This is quite bad
Based on estimates for the next years, FULC will show a decrease in Revenue. The Revenue will decrease by -8.96% on average per year.
EPS Next Y-444.77%
EPS Next 2Y-136.07%
EPS Next 3Y-85.58%
EPS Next 5Y-27.38%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-8.96%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for FULC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FULC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as FULC's earnings are expected to decrease with -85.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-136.07%
EPS Next 3Y-85.58%
5. Dividend
5.1 Amount
No dividends for FULC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
10.92
-0.39 (-3.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners99.42%
Inst Owner Change-1.61%
Ins Owners0.62%
Ins Owner Change-0.39%
Market Cap590.99M
Revenue(TTM)80.00M
Net Income(TTM)-9.72M
Analysts81.33
Price Target19.38 (77.47%)
Short Float %5.62%
Short Ratio1.98
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.94%
Min EPS beat(2)-3.46%
Max EPS beat(2)5.34%
EPS beat(4)3
Avg EPS beat(4)3.49%
Min EPS beat(4)-3.46%
Max EPS beat(4)6.63%
EPS beat(8)7
Avg EPS beat(8)870.55%
EPS beat(12)10
Avg EPS beat(12)583.7%
EPS beat(16)12
Avg EPS beat(16)438.83%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)39.45%
PT rev (3m)71.61%
EPS NQ rev (1m)3.05%
EPS NQ rev (3m)-3.63%
EPS NY rev (1m)-0.75%
EPS NY rev (3m)-2.73%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 7.39 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.98 | ||
| P/tB | 2.98 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.18
EYN/A
EPS(NY)-1.23
Fwd EYN/A
FCF(TTM)-1.12
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS1.48
BVpS3.67
TBVpS3.67
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.53% | ||
| ROE | -4.9% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-29.99%
ROA(5y)-35.8%
ROE(3y)-33.54%
ROE(5y)-42.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 27.34% | ||
| Cap/Sales | 0.48% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 17.7 | ||
| Quick Ratio | 17.7 | ||
| Altman-Z | 19.68 |
F-Score4
WACC9.36%
ROIC/WACCN/A
Cap/Depr(3y)40.72%
Cap/Depr(5y)49.27%
Cap/Sales(3y)16.46%
Cap/Sales(5y)14.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-280.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.43%
EPS Next Y-444.77%
EPS Next 2Y-136.07%
EPS Next 3Y-85.58%
EPS Next 5Y-27.38%
Revenue 1Y (TTM)2752.05%
Revenue growth 3Y61.03%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-8.96%
EBIT growth 1Y82.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-228.89%
EBIT Next 3Y-74.52%
EBIT Next 5YN/A
FCF growth 1Y31.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.4%
OCF growth 3YN/A
OCF growth 5YN/A
FULCRUM THERAPEUTICS INC / FULC FAQ
What is the fundamental rating for FULC stock?
ChartMill assigns a fundamental rating of 4 / 10 to FULC.
What is the valuation status of FULCRUM THERAPEUTICS INC (FULC) stock?
ChartMill assigns a valuation rating of 0 / 10 to FULCRUM THERAPEUTICS INC (FULC). This can be considered as Overvalued.
Can you provide the profitability details for FULCRUM THERAPEUTICS INC?
FULCRUM THERAPEUTICS INC (FULC) has a profitability rating of 1 / 10.
How financially healthy is FULCRUM THERAPEUTICS INC?
The financial health rating of FULCRUM THERAPEUTICS INC (FULC) is 9 / 10.
Can you provide the expected EPS growth for FULC stock?
The Earnings per Share (EPS) of FULCRUM THERAPEUTICS INC (FULC) is expected to decline by -444.77% in the next year.